Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Biogen
Age
18–70
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Must have a diagnosis of primary-progressive, secondary-progressive, progressive-relapsing, or relapsing-remitting MS per revised McDonald Committee criteria \[McDonald 2001; Polman 2005\] as defined by Lublin and Reingold \[Lublin and Reingold 1996\] of at least 3 months duration
Must have an Expanded Disability Status Scale (EDSS) score of 4 to 7, inclusive
Must have walking impairment, as deemed by the Investigator
You may not be if
History of human immunodeficiency virus (HIV)
Presence of acute or chronic hepatitis. Subjects who have evidence of prior hepatitis infection that has been serologically confirmed as resolved are not excluded from study participation
Known allergy to fampridine, pyridine-containing substances, or any of the inactive ingredients in the prolonged-release fampridine tablet
Creatinine clearance (CrCl) of \<80 mL/min
History of malignant disease
Presence of pulmonary disease
A body mass index (BMI) ≥40 (BMI formula: BMI = mass \[kg\]/\[height(m)\]2)
Clareo Health | Efficacy and Safety Study of Prolonged-Release Fampridine in Participants With Multiple Sclerosis
